<DOC>
	<DOCNO>NCT00507507</DOCNO>
	<brief_summary>The main objective study evaluate antiviral activity tenofovir disoproxil fumarate ( tenofovir DF ) monotherapy versus emtricitabine ( FTC ) plus tenofovir DF combination therapy treatment chronic hepatitis B ( HBV ) participant immune tolerant phase HBV infection . The efficacy tenofovir DF monotherapy versus FTC plus tenofovir DF combination therapy evaluate suppression virus ( decrease HBV DNA ) , serological response ( generation antibody virus ) , biochemical response ( change liver enzymes ) , development drug-resistant mutation . The safety tolerability tenofovir DF monotherapy FTC plus tenofovir DF evaluate routine monitoring adverse event change laboratory parameter . Participants randomize 1:1 ratio receive tenofovir DF monotherapy FTC plus tenofovir DF . All subject continue blind study medication last subject reach Week 192 . Participants permanently discontinue study drug ( Week 192 ) follow 24-week treatment-free follow-up period , initiation alternative HBV therapy , whichever occur first . Subjects discontinue study drug Week 48 hepatitis B surface antigen ( HBsAg ) loss seroconversion antibody hepatitis B surface antigen ( anti-HBs ) , however , return regularly schedule Week 192 every 16 week thereafter last subject reach Week 192 .</brief_summary>
	<brief_title>A Study Compare Tenofovir DF Versus Combination Emtricitabine Plus Tenofovir DF Treatment Chronic Hepatitis B Patients With Normal Alanine Aminotransferase ( ALT )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>Chronic HBV infection , define positive serum HBsAg least 6 month HBsAg positive &gt; 3 month positive immunoglobulin G antibody hepatitis B core antigen 18 69 year age , inclusive Hepatitis B e antigen ( HBeAg ) positive HBV DNA ≥ 10^8 copies/mL ALT ≤ upper limit normal range ( ULN ) Willing able provide write informed consent Negative serum betahuman chorionic gonadotropin ( female childbearing potential ) Calculated creatinine clearance ≥ 70 mL/min Hemoglobin ≥ 10 g/dL Neutrophils ≥ 1,500/mm^3 No prior oral HBV therapy ( eg , nucleotide and/or nucleoside therapy investigational agent HBV infection ) Pregnant woman , woman breast feeding , believe may wish become pregnant course study Males females reproductive potential unwilling use effective method contraception study Decompensated liver disease define direct ( conjugate ) bilirubin &gt; 1.2 x ULN , prothrombin time &gt; 1.2 x ULN , platelets &lt; 150,000/mm^3 , serum albumin &lt; 3.5 g/dL , prior history clinical hepatic decompensation ( eg , ascites , jaundice , encephalopathy , variceal hemorrhage ) Received interferon ( pegylated ) therapy within 6 month screen visit Alphafetoprotein &gt; 50 ng/mL Evidence hepatocellular carcinoma Coinfection hepatitis C virus ( serology ) , HIV , hepatitis D virus Significant renal , cardiovascular , pulmonary , neurological disease Received solid organ bone marrow transplantation Was currently receive therapy immunomodulators ( eg , corticosteroid , etc . ) , investigational agent , nephrotoxic agent , agent susceptible modify renal excretion Had proximal tubulopathy Known hypersensitivity study drug , metabolite , formulation excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>tenofovir</keyword>
	<keyword>monotherapy</keyword>
	<keyword>emtricitabine</keyword>
	<keyword>combination</keyword>
	<keyword>hepatitis B</keyword>
</DOC>